Search

Your search keyword '"ROSENLUND, SIGNE"' showing total 29 results
Start Over Author "ROSENLUND, SIGNE"
29 results on '"ROSENLUND, SIGNE"'

1. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Author

Zimmermann, Silke, Rädisch, Brit, Hävemeier, Anika, Busmann, Annette, Wittkop, Ulrike, Neuhaus, Barbara, Ax-Smolarski, Regina, Zieglschmid, Veit, Bollweber, Eva, Wölk, Heidrun, Curovic, Viktor R., Tougaard, Ninna H., Eickhoff, Mie K., Pilemann-Lyberg, Sascha, Winther, Signe A., Rosenlund, Signe V., Hansen, Tine W., von Scholten, Bernt J., Hansen, Christian S., Zobel, Emilie H., Laursen, Jens C., Theilade, Simone, Jelstrup, Lone, Juhl, Tina R., Riis, Dorthe, Hermann, Jessie A., Lundgaard, Anne G., Halkjær, Maja L.D., Aabo, Lene, Frost Lerche, Therese, Lajer, Maria, Stefansen, Rikke J., Campbell, Maria A., Durban, Annika, Raad, Julia, Prigge, Michael, Schiemann, Marco, Wilson, Robbie, Kean, Sharon, Douglas, Elizabeth, Surtees, Pamela, Gant, Christina, Yeung, Stanley M.H., Hagedoorn, Ilse, Flynn, Joanne, Galloway, Joe, Brooksbank, Katriona, Aparicio, Carolina, Iliev, Ilian P., Nones, Francesco, Lo Bue, Francesca, Melacini, Daniela, Cugini, Daniela, Prandini, Silvia, Lecchi, Verusca, Yakymchuk, Svitlana, Gherardi, Giulia, Villa, Alessandro, Villa, Davide, Gaspari, Flavio, Cannata, Antonio N., Ferrari, Silvia, Stucchi, Nadia, Albrechtová, Šárka, Eldeik, Elina, Amanaki, Renata, Fernandez-Fernandez, Beatriz, Sanchez-Rodriguez, Jinny, Vázquez, Clotilde, Sanz, Ana B., Sanchez-Niño, Maria D., Ramos, Adrian M., Gonzalo, Maria Á., Schmidt, Ulrike, Selim, Gjulsen, Gjorgovski, Tatjana, Stratrova, Slavica S., Stojceva-Taneva, Olivera, Schutten-Westerneng, Petra, Wierbos, Brenda, Huvers, Frank, De Bruin, Anneke K., Lapauw, Bruno, de Man, Elsie, Rokegem, Kelly, Inion, Sabien, Kreutzmann, Kristin, Dewettinck, Isabelle, Boukens-de Graaf, Caroline, Clerc-de Jong, Ferrina, Entius, Jannet, Nannings, Marian, van Steenderen, Suzy, Petry, Friedrich W., Kilic, Ceyda, Tofte, Nete, Lindhardt, Morten, Adamova, Katarina, Bakker, Stephan J L, Beige, Joachim, Beulens, Joline W J, Birkenfeld, Andreas L, Currie, Gemma, Delles, Christian, Dimos, Ingo, Francová, Lidmila, Frimodt-Møller, Marie, Girman, Peter, Göke, Rüdiger, Havrdova, Tereza, Heerspink, Hiddo J L, Kooy, Adriaan, Laverman, Gozewijn D, Mischak, Harald, Navis, Gerjan, Nijpels, Giel, Noutsou, Marina, Ortiz, Alberto, Parvanova, Aneliya, Persson, Frederik, Petrie, John R, Ruggenenti, Piero L, Rutters, Femke, Rychlík, Ivan, Siwy, Justyna, Spasovski, Goce, Speeckaert, Marijn, Trillini, Matias, Zürbig, Petra, von der Leyen, Heiko, and Rossing, Peter

Published
2020
Full Text
View/download PDF

2. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Author

Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Gonzalez-Orozco, L, Gumprecht, J, Haddad, E, Hansen, T K, Hart, T, Hasan, S, Hella, B, Heller, S, Hellgren, M, Hewitt, M, Hietaniemi, S, Hitz, M, Houser, P, Huntley, R, Jackson, R, Jakobsen, P E, Kapoor, A, Kargina, L, Kazakova, E, Khan, K, Klein, E, Knoble, H, Krasnopeeva (Kabachkova), N, Krzeminski, A, Kunitsyna, M, Lawhead, J, Levin, K, Levin, P, Lewy-Alterbaum, L, Lindmark, S, Lindsay, R, Luts, A, Lysenko, T, Madsbad, S, Maxwell, T, Mbogua, C, Mcknight, J, Metsärinne, K, Milovanova, T, Morawski, E, Mosenzon, O, Nabriski, D, Nguyen, H, Nicol, P, Nieminen, S, Nikkola, A, Norwood, P, O'Donnell, P, Odugbesan, A, Parker, J, Pergaeva, Y, Peskov, A, Plevin, S, Pouzar, J, Pratley, R, Reed, J, Rossing, P, Sathyapalan, T, Sergeeva-Kondrachenko, M, Shaikh, Z, Shamkhalova, M, Shehadeh, N, Shlesinger, Y, Silver, R, Snyder, B, Soufer, J, Strand, J, Sulosaari, S, Tirosh, A, Traylor, H, Uhlenius, N, Vagapova, G, Yanovskaya, M, Zarutskaya, L, Zhdanova, E, Mosenzon, Ofri, Blicher, Thalia Marie, Rosenlund, Signe, Eriksson, Jan W, Heller, Simon, Hels, Ole Holm, Pratley, Richard, Sathyapalan, Thozhukat, and Desouza, Cyrus

Published
2019
Full Text
View/download PDF

8. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Author

Tofte, Nete, primary, Lindhardt, Morten, additional, Adamova, Katarina, additional, Bakker, Stephan J L, additional, Beige, Joachim, additional, Beulens, Joline W J, additional, Birkenfeld, Andreas L, additional, Currie, Gemma, additional, Delles, Christian, additional, Dimos, Ingo, additional, Francová, Lidmila, additional, Frimodt-Møller, Marie, additional, Girman, Peter, additional, Göke, Rüdiger, additional, Havrdova, Tereza, additional, Heerspink, Hiddo J L, additional, Kooy, Adriaan, additional, Laverman, Gozewijn D, additional, Mischak, Harald, additional, Navis, Gerjan, additional, Nijpels, Giel, additional, Noutsou, Marina, additional, Ortiz, Alberto, additional, Parvanova, Aneliya, additional, Persson, Frederik, additional, Petrie, John R, additional, Ruggenenti, Piero L, additional, Rutters, Femke, additional, Rychlík, Ivan, additional, Siwy, Justyna, additional, Spasovski, Goce, additional, Speeckaert, Marijn, additional, Trillini, Matias, additional, Zürbig, Petra, additional, von der Leyen, Heiko, additional, Rossing, Peter, additional, Zimmermann, Silke, additional, Rädisch, Brit, additional, Hävemeier, Anika, additional, Busmann, Annette, additional, Wittkop, Ulrike, additional, Neuhaus, Barbara, additional, Ax-Smolarski, Regina, additional, Zieglschmid, Veit, additional, Bollweber, Eva, additional, Wölk, Heidrun, additional, Curovic, Viktor R., additional, Tougaard, Ninna H., additional, Eickhoff, Mie K., additional, Pilemann-Lyberg, Sascha, additional, Winther, Signe A., additional, Rosenlund, Signe V., additional, Hansen, Tine W., additional, von Scholten, Bernt J., additional, Hansen, Christian S., additional, Zobel, Emilie H., additional, Laursen, Jens C., additional, Theilade, Simone, additional, Jelstrup, Lone, additional, Juhl, Tina R., additional, Riis, Dorthe, additional, Hermann, Jessie A., additional, Lundgaard, Anne G., additional, Halkjær, Maja L.D., additional, Aabo, Lene, additional, Frost Lerche, Therese, additional, Lajer, Maria, additional, Stefansen, Rikke J., additional, Campbell, Maria A., additional, Durban, Annika, additional, Raad, Julia, additional, Prigge, Michael, additional, Schiemann, Marco, additional, Wilson, Robbie, additional, Kean, Sharon, additional, Douglas, Elizabeth, additional, Surtees, Pamela, additional, Gant, Christina, additional, Yeung, Stanley M.H., additional, Hagedoorn, Ilse, additional, Flynn, Joanne, additional, Galloway, Joe, additional, Brooksbank, Katriona, additional, Aparicio, Carolina, additional, Iliev, Ilian P., additional, Nones, Francesco, additional, Lo Bue, Francesca, additional, Melacini, Daniela, additional, Cugini, Daniela, additional, Prandini, Silvia, additional, Lecchi, Verusca, additional, Yakymchuk, Svitlana, additional, Gherardi, Giulia, additional, Villa, Alessandro, additional, Villa, Davide, additional, Gaspari, Flavio, additional, Cannata, Antonio N., additional, Ferrari, Silvia, additional, Stucchi, Nadia, additional, Albrechtová, Šárka, additional, Eldeik, Elina, additional, Amanaki, Renata, additional, Fernandez-Fernandez, Beatriz, additional, Sanchez-Rodriguez, Jinny, additional, Vázquez, Clotilde, additional, Sanz, Ana B., additional, Sanchez-Niño, Maria D., additional, Ramos, Adrian M., additional, Gonzalo, Maria Á., additional, Schmidt, Ulrike, additional, Selim, Gjulsen, additional, Gjorgovski, Tatjana, additional, Stratrova, Slavica S., additional, Stojceva-Taneva, Olivera, additional, Schutten-Westerneng, Petra, additional, Wierbos, Brenda, additional, Huvers, Frank, additional, De Bruin, Anneke K., additional, Lapauw, Bruno, additional, de Man, Elsie, additional, Rokegem, Kelly, additional, Inion, Sabien, additional, Kreutzmann, Kristin, additional, Dewettinck, Isabelle, additional, Boukens-de Graaf, Caroline, additional, Clerc-de Jong, Ferrina, additional, Entius, Jannet, additional, Nannings, Marian, additional, van Steenderen, Suzy, additional, Petry, Friedrich W., additional, and Kilic, Ceyda, additional

Published
2020
Full Text
View/download PDF

10. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Author

Mosenzon, Ofri, primary, Blicher, Thalia Marie, additional, Rosenlund, Signe, additional, Eriksson, Jan W, additional, Heller, Simon, additional, Hels, Ole Holm, additional, Pratley, Richard, additional, Sathyapalan, Thozhukat, additional, Desouza, Cyrus, additional, Abramof, R, additional, Alpenidze, D, additional, Aronoff, S, additional, Astamirova, K, additional, Barker, B, additional, Bedel, G, additional, Belousova, L, additional, Benson, M, additional, Beshay, I, additional, Biggs, W, additional, Blaze, K, additional, Bogdanski, P, additional, Busch, R, additional, Chaidarun, S, additional, Chandran, S, additional, Chang, A, additional, Chilka, S, additional, Cleland, A, additional, Connery, L, additional, Cornett, G, additional, Delgado, B, additional, Desouza, C, additional, Donner, T, additional, Eliasson, K, additional, Eriksson, J, additional, Folkerth, S, additional, Forshaw, K, additional, Frandsen, H A, additional, Frolova, E, additional, Gandy, W, additional, Gatipon, G, additional, Golovach, A, additional, Gonzalez-Orozco, L, additional, Gumprecht, J, additional, Haddad, E, additional, Hansen, T K, additional, Hart, T, additional, Hasan, S, additional, Hella, B, additional, Heller, S, additional, Hellgren, M, additional, Hewitt, M, additional, Hietaniemi, S, additional, Hitz, M, additional, Houser, P, additional, Huntley, R, additional, Jackson, R, additional, Jakobsen, P E, additional, Kapoor, A, additional, Kargina, L, additional, Kazakova, E, additional, Khan, K, additional, Klein, E, additional, Knoble, H, additional, Krasnopeeva (Kabachkova), N, additional, Krzeminski, A, additional, Kunitsyna, M, additional, Lawhead, J, additional, Levin, K, additional, Levin, P, additional, Lewy-Alterbaum, L, additional, Lindmark, S, additional, Lindsay, R, additional, Luts, A, additional, Lysenko, T, additional, Madsbad, S, additional, Maxwell, T, additional, Mbogua, C, additional, Mcknight, J, additional, Metsärinne, K, additional, Milovanova, T, additional, Morawski, E, additional, Mosenzon, O, additional, Nabriski, D, additional, Nguyen, H, additional, Nicol, P, additional, Nieminen, S, additional, Nikkola, A, additional, Norwood, P, additional, O'Donnell, P, additional, Odugbesan, A, additional, Parker, J, additional, Pergaeva, Y, additional, Peskov, A, additional, Plevin, S, additional, Pouzar, J, additional, Pratley, R, additional, Reed, J, additional, Rossing, P, additional, Sathyapalan, T, additional, Sergeeva-Kondrachenko, M, additional, Shaikh, Z, additional, Shamkhalova, M, additional, Shehadeh, N, additional, Shlesinger, Y, additional, Silver, R, additional, Snyder, B, additional, Soufer, J, additional, Strand, J, additional, Sulosaari, S, additional, Tirosh, A, additional, Traylor, H, additional, Uhlenius, N, additional, Vagapova, G, additional, Yanovskaya, M, additional, Zarutskaya, L, additional, and Zhdanova, E, additional

Published
2019
Full Text
View/download PDF

12. Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes.

Author

Ranjan, Ajenthen G., Rosenlund, Signe V., Hansen, Tine W., Rossing, Peter, Andersen, Steen, and Nørgaard, Kirsten

Subjects
*TYPE 1 diabetes, *ALBUMINURIA, *GLYCOSYLATED hemoglobin, *INSULIN pumps, *INSULIN, *BLOOD sugar analysis, *RESEARCH, *TIME, *BLOOD sugar monitoring, *RESEARCH methodology, *HYPOGLYCEMIC agents, *MEDICAL cooperation, *EVALUATION research, *TREATMENT effectiveness, *COMPARATIVE studies, *CREATININE, *LONGITUDINAL method, *DISEASE complications
Abstract

Objective: To investigate the association between treatment-induced change in continuous glucose monitoring (CGM) time in range (TIR) and albuminuria in persons with type 1 diabetes (T1D) treated with sensor-augmented insulin pumps (SAP).Research Design and Methods: Twenty-six out of 55 participants with albuminuria and multiple daily injection therapy (25% females; median 51 [interquartile range 46-63] years of age; glycated hemoglobin A1c (HbA1c) 75 [68-88] mmol/mol [9.0% (8.4-10.4%)]; and urinary albumin-to-creatinine ratio (UACR) 89 [37-250] mg/g) were in a randomized controlled trial assigned to SAP therapy for 1 year. Anthropometrics, CGM data, and blood and urine samples were collected every 3 months.Results: Mean change (95% CI) in percentage of TIR (%TIR) was 13.2% (6.2; 20.2), in HbA1c was -14.4 (-17.4; -10.5) mmol/mol (-1.3% [-1.6; -1.0]), and in UACR was -15% (-38; 17) (all P < 0.05). UACR decreased by 19% (10; 28) per 10% increase in %TIR (P = 0.04), 18% (1; 30) per 10 mmol/mol decrease in HbA1c (P = 0.07), and 31% per 10-mmHg decrease in mean arterial pressure (P < 0.001).Conclusions: In this longitudinal study, treatment-induced increase in %TIR was significantly associated with decrease in albuminuria in T1D. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

13. The effect of liraglutide on renal function:A randomized clinical trial

Author

von Scholten, Bernt J., Persson, Frederik, Rosenlund, Signe, Hovind, Peter, Faber, Jens, Hansen, Tine W., and Rossing, Peter

Subjects
liraglutide, diabetic nephropathy, randomized trial, GLP-1
Abstract

Aims: Among patients with type 2 diabetes and albuminuria, cardiorenal morbidity and mortality are high despite multifactorial treatment. Short-term reduction in albuminuria is considered suggestive of long-term renoprotective effects. We evaluated the renal effects of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide on top of multifactorial care, including renin-angiotensin-system (RAS)-inhibition. Materials and methods: Randomized, double-blind, placebo-controlled, cross-over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order. The primary endpoint was change in 24-h urinary albumin excretion rate (UAER). Results: A total of 32 patients were randomized and 27 completed the study. After placebo treatment, geometric mean (IQR) UAER was 199 (81-531) mg/24-h, mean (SD) measured GFR (mGFR) 75 (36) mL/min/1.73 m2, 24-h blood pressure 145/80 (15/8) mm Hg and HbA1c 61 (11) mmol/mol. Liraglutide reduced HbA1c by 8 (95% CI: 5; 11) mmol/mol (P 2 (P =.15), and change in 24-h systolic blood pressure was −5 (95% CI: −10; 0) mm Hg (P =.07). In multivariate regression models, change in UAER was associated with change in 24-h systolic blood pressure (P =.025) but not with change in HbA1c, weight or mGFR (P ≥.14), overall model R 2 =.39. Conclusions: Our placebo-controlled randomized trial suggests that liraglutide has renoprotective effects on top of multifactorial treatment, including RAS-inhibition, in patients with type 2 diabetes and albuminuria.

Published
2017

14. Patient-reported outcome after total hip arthroplasty: comparison between lateral and posterior approach

Author

Rosenlund, Signe, Broeng, Leif, Holsgaard-Larsen, Anders, Jensen, Carsten, and Overgaard, Søren

Subjects
Male, Hip, Arthroplasty, Replacement, Hip, Recovery of Function, Middle Aged, Severity of Illness Index, Osteoarthritis, Hip, Treatment Outcome, Double-Blind Method, Quality of Life, Humans, Female, Patient Reported Outcome Measures, Exercise, Gait, Aged, Follow-Up Studies, Pain Measurement
Abstract

Background and purpose — Criticism of the lateral approach (LA) for hip arthroplasty is mainly based on the risk of poor patient-reported outcomes compared to the posterior approach (PA). However, there have been no controlled studies comparing patient-reported outcomes between them. In this randomized controlled trial, we tested the hypothesis that patient-reported outcomes are better in patients who have undergone total hip arthroplasty (THA) with PA than in those who have undergone THA with LA, 12 months postoperatively. Patients and methods — 80 patients with hip osteoarthritis (mean age 61 years) were randomized to THA using PA or the modified direct LA. We recorded outcome measures preoperatively and 3, 6, and 12 months postoperatively using the Hip Disability and Osteoarthritis Outcome Score–Physical Function Short Form (HOOS-PS) as the primary outcome. Secondary outcomes were HOOS-Pain, HOOS-Quality-Of-Life, EQ-5D, UCLA Activity Score, and limping. Results — We found no statistically significant difference in the improvements in HOOS-PS between the treatment groups at 12-month follow-up. All secondary outcomes showed similar results except for limping, where PA patients improved significantly more than LA patients. Interpretation — Contrary to our hypothesis, patients treated with PA did not improve more than patients treated with LA regarding physical function, pain, physical activity, and quality of life 12 months postoperatively. However, limping was more pronounced in the LA patients.

Published
2017
Full Text
View/download PDF

24. The efficacy of modified direct lateral versus posterior approach on gait function and hip muscle strength after primary total hip arthroplasty at 12 months follow-up. An explorative randomised controlled trial.

Author

Rosenlund, Signe, Broeng, Leif, Overgaard, Søren, Jensen, Carsten, and Holsgaard-Larsen, Anders

Subjects
*HIP joint diseases diagnosis, *OSTEOARTHRITIS diagnosis, *HIP joint, *ISOMETRIC exercise, *BIOMECHANICS, *DIAGNOSIS, *GAIT in humans, *PATIENT aftercare, *MUSCLE strength, *ORTHOPEDICS, *TOTAL hip replacement, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *ANATOMY
Abstract

Background The lateral and the posterior approach are the most commonly used procedures for total hip arthroplasty. Due to the detachment of the hip abductors, lateral approach is claimed to cause reduced hip muscle strength and altered gait pattern. However, this has not been investigated in a randomised controlled trial. The aim was to compare the efficacy of total hip arthroplasty performed by lateral or posterior approach on gait function and hip muscle strength up to 12 months post-operatively. We hypothesised that posterior approach would be superior to lateral approach. Methods Forty-seven patients with primary hip osteoarthritis were randomised to total hip arthroplasty with either posterior or lateral approach and evaluated pre-operatively, 3 and 12 months post-operatively using 3-dimensional gait analyses as objective measures of gait function, including Gait Deviation Index, temporo–spatial parameters and range of motion. Isometric maximal hip muscle strength in abduction, flexion and extension was also tested. Findings Post-operatively, no between-group difference in gait function was observed. However, both hip abductor and flexor muscle strength improved more in the posterior approach group: − 0.20(Nm/kg)[95%CI:− 0.4 to 0.0] and − 0.20(Nm/kg)[95%CI:− 0.4 to 0.0], respectively. Interpretation Contrary to our first hypothesis, the overall gait function in the posterior approach group did not improve more than in the lateral approach group. However, in agreement with our second hypothesis, patients in the posterior approach group improved more in hip abductor and flexor muscle strength at 12 months. Further investigation of the effect of reduced maximal hip muscle strength on functional capacity is needed. ClinicalTrials.gov. No.: NCT01616667 [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

28. Bacteriological aetiology and antimicrobial treatment of pleural empyema.

Author

Meyer, Christian N., Rosenlund, Signe, Nielsen, Jannie, and Friis-Møller, Alice

Subjects
*BACTERIAL disease complications, *METRONIDAZOLE, *ANTIBIOTICS, *PENICILLIN, *ANAEROBIC bacteria, *BACTERIAL diseases, *COMBINATION drug therapy, *CHI-squared test, *COMPUTER software, *CONFIDENCE intervals, *EMPYEMA, *ENTEROBACTERIACEAE, *EPIDEMIOLOGY, *FISHER exact test, *MICROBIAL sensitivity tests, *PLEURA, *STAPHYLOCOCCAL diseases, *STAPHYLOCOCCUS aureus, *STREPTOCOCCAL diseases, *DATA analysis, *MULTIPLE regression analysis, *RETROSPECTIVE studies, *THERAPEUTICS
Abstract

Background: Our aims were to describe the aetiologies of culture-positive pleural infections and to evaluate the choice of empiric antimicrobial treatment regimens according to antimicrobial sensitivity, and to evaluate the possible influence of this on outcome. Methods: All cases over a 9-y period were identified from 3 hospitals using the laboratory databases of the clinical microbiology departments, and were verified by evaluating the medical records. Results: We identified 291 isolates in pleural fluid cultures from 158 patients. These included viridans streptococci (25%), Staphylococcus aureus (18%), anaerobic bacteria (17%), Enterobacteriaceae (12%), Staphylococcus epidermidis (10%), and Streptococcus pneumoniae (7%), with differences between nosocomial and community-acquired infections. The mortality (overall 27%) was highest among the patients with Enterobacteriaceae (50%) and S. aureus (36%) infections, and in patients with mixed infections (34%). The actual empiric treatment or the recommended penicillin plus metronidazole had low antimicrobial coverage (49%) compared to the proposed cefuroxime plus metronidazole (78%). Thoracentesis was often delayed (median 2 days). The adequacy of empiric antimicrobial therapy was independently correlated with mortality (odds ratio 0.43, 95% confidence interval 0.30--0.62). Conclusions: The early diagnosis of pleural infection could be optimized. In this North-European patient population, we suggest that the recommended empiric antimicrobial treatment be changed to cefuroxime plus metronidazole for community-acquired and nosocomial infections. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

29. [Acrodermatitis chronica atrophicans can be difficult to diagnose].

Author

Rosenlund S, Bækgaard N, and Menné T

Subjects
Acrodermatitis drug therapy, Acrodermatitis pathology, Adult, Atrophy, Borrelia burgdorferi isolation & purification, Chronic Disease, Diagnosis, Differential, Humans, Lyme Disease drug therapy, Lyme Disease pathology, Male, Skin pathology, Toes pathology, Acrodermatitis diagnosis, Lyme Disease diagnosis
Abstract

A healthy 29 year-old man developed over four years a slowly increasing swelling and violet discolouring of the third toe on his left foot. He was examined by several specialists and an amputation was recommended since the condition was unknown and aggravating. On suspicion of Borrelia infection the patient was prescribed penicillin treatment for 28 days with convincing effect. Serologic tests showed increased Borrelia titer. Biopsy showed chronic inflammation without any suspicion of malignity. Denmark is endemic for borreliosis and per year approximately 50 cases develop acrodermatitis chronic atrophicans.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results